Search Results 131-140 of 17260 for protein intake optimization

1. Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... protein electrophoresis and/or immunoglobulin M ... Known psychiatric or substance abuse disorders that would ...

2. A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... protein that binds bone morphogenic protein) ... Requirement for concomitant medications that ...

3. Study of Sparsentan in Patients with Primary Focal Segmental Glomerulosclerosis - Mayo Clinic

   ... optimal dosages and risks/benefits. ... The patient has biopsy-proven FSGS lesion(s) or documentation of a genetic mutation in a podocyte protein associated with ...

4. WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... requirements; Willing to return to ... AZD1775 is an inhibitor of breast cancer resistance protein.

5. Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... Serum albumin > 28 g/L - Lipase < 2 ULN - Urine protein/ creatinine ratio (UPCR) =< 1. ... Psychiatric illness/ ...

6. Belantamab, Lenalidomide, and Daratumumab for Newly-diagnosed Multiple Myeloma - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... Daratumumab is a drug that is a monoclonal antibody that is directed towards a protein on the myeloma cell.

7. A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... Prior treatment with anti-cytotoxic T-lymphocyte-associated protein ... Clinical signs or symptoms of GI ...

8. Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN) - Mayo Clinic

   ... optimal dosages and risks/benefits. In the ... requirements. * Screening urine protein/creatinine ratio (uPCR) ≥ 0.75 g/g or urine protein ≥ 1.0 g/day

9. Preventing glomerulonephritis after kidney transplant - Mayo Clinic

   "Certain recurrent monoclonal protein-related ... Optimal time to refer for kidney transplant evaluation ... Admissions Requirements · Degree Programs.

10. A Study of Cediranib and Olaparib Combined, Compared to Either Drug Alone, or to a Standard Chemotherapy in Treating Patients who have a Return of Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... Urine protein: creatinine ratio urine protein ... requirements; Known human immunodeficiency virus ...